Rimidi provides a platform that aggregates patient-generated data, clinical information, and practice guidelines to enable clinicians to personalize care and identify individuals who may benefit from specific therapeutic approaches. The solution integrates with electronic medical record systems to deliver a workflow experience for clinicians at the point of care. The company focuses on chronic disease management and offers clinical analytics and software to support care teams. Led by CEO Josh Claman and formerly known as Rimidi Diabetes, the company is based in Atlanta, GA. Rimidi closed a $6.575M Series A-1 financing from investors including Eli Lilly, Turner Investments, Cox Enterprises, Village Capital, The Jump Fund and JAMB Global. It intends to use the proceeds to accelerate growth and market penetration. Rimidi develops a cloud-based platform for diabetes and chronic disease management. Led by CEO Lucienne Ide, its flagship product, Diabetes+Me™, lets patients track health and lifestyle data and access medical and nutritional information. Care teams leverage the platform’s proprietary analytics for treatment decision-making, population management and improved care. The company said it will use the newly received funds to expand into additional markets. The amount of the investment was not disclosed. Rimidi previously received funding from SOURCE (a partnership between the Hitachi Foundation, Investor’s Circle and Village Capital) and the JumpFund.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2018